EFFICACY OF TARGETED THERAPIES IN HEMATOLOGIC MALIGNANCIES: A CLINICAL OUTCOME STUDY

Abstract

Clinical outcome trial that establishes the effectiveness of particular medicines in the treatment of haematologic malignancies considering the response of patients, the progress-free survival (PFS), and the overall survival (OS).  A group of patients with different types of blood cancers including chronic myeloid leukaemia (CML), non-Hodgkin lymphoma (NHL) and acute myeloid leukaemia (AML) were treated with specific drugs, i.e., tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and immune checkpoint inhibitors.  The paper gives comparison data of the efficacy of treatments, sequence of adverse events and long term results of the various therapeutic treatment.  The results imply that the PFS and OS of patients taking TKIs were significantly greater and the side effects were less than the ones taking standard treatment.  Treatment of NHL with monoclonal antibody was demonstrated to show positive percentages of progression free survival especially in recurring cases.  The therapies involving the use of immuno-checkpoint inhibitors were found to be more effective in the AML in combination with chemotherapy, that is, there was synergy.  The results suggest that increased emphasis on specific drugs is becoming pertinent in the management of blood malignancies and that the patients need customised treatment regimen to obtain the best results..